focus -WSS

focus

author：hotspot 2025-09-30 00:49:59 - browse：1

Since the pandemic, patients have become increasingly comfortable with getting their medications online. Direct-to-consumer telehealth has made it easy to schedule a virtual visit and get a script, sometimes within minutes, with prescriptions shipped to your doorstep.

Now, Big Pharma is ready to get in on the action.

In early January, Eli Lilly announced a platform that allows patients to access and fill prescriptions for its drugs online, timing the news to the availability of its obesity medication Zepbound. Using LillyDirect, patients click into a pipeline for their condition — obesity, diabetes, or migraine — and are routed to telehealth sites that can prescribe them one of Lilly’s drugs if they’re eligible. An integration with online pharmacy Truepill will deliver the meds.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： The (many) problems with a new study criticizing cancer screening

WSS

How generative AI is inspiring dreams of a health data revolution

Listen: Biogen's potential pivot, & Illumina's next chapter

Stem cell treatment guidelines are released by FDA

House transparency, PBM reform bill gains bipartisan support

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The 10 drugs up first for Medicare price negotiation

hotspot

focus

hotspot

Virginia high school admissions case could be legal follow

What drug price negotiations mean for Medicare Part D

How to save PrEP access — and even expand it

Amazon on where the company's health care bets are headed next

Medical records are filled with copy

Top private equity targets in 2023: cardiology, clinical trials, lasers

In age of alternative facts, a scholarly course on calling out crap

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Medical leaders decry Supreme Court decision on affirmative action

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

Why Novartis is going to walk from its acquisition of MorphoSys

How to protect patients from sexual assault

Weighted lottery helped low

Surgery pushed Ben Carson to fame

Problems with a popular proposal to regulate AI in health care

Devoted Health’s losses in Medicare Advantage persist

knowledge

explore

explore

focus